Microorganisms continue to be a major source for innovative antibiotics. Ubiquitously found but understudied soil-dwelling predatory myxobacteria have proven to be a rich source of bioactive compounds . Myxovalargin (Myx) was described in 1983 from Myxococcus fulvus strain Mx f65 as displaying activity against a broad panel of bacteria, exhibiting minimum inhibitory concentrations (MICs) between 0.3-5 µg/mL for Gram-positive and 6-100 µg/ml for Gram-negative bacteria, respectively . Myxovalargins comprise some congeners with Myxovalargin A (MyxA) as the predominant species. They were shown to most likely act on protein biosynthesis in bacteria and also exhibited an additional unspecific membrane effect at concentrations above 18 µg/ml, causing damage to eukaryotic cells including human erythrocytes, but did not inhibit eukaryotic translation at either dose . The efficacy in mouse models of infection with Staphylococcus aureus, Streptococcus pyogenes and Escherichia coli could be shown at median efficacious doses (ED50) of 2.3, 2 x 0.4 and 2 x 10 mg/kg subcutaneously, respectively. However, compound development was stopped because of the limitations in compound availability and potential narrow therapeutic index where the median lethal dose (LD50) in mice was determined at 10 mg/kg s.c.. To our knowledge, neither the total synthesis nor a description of the biosynthetic pathway of Myx have been described.